Update Phase 2b CERE-120
Ceregene Advances Phase 2b CERE-120 (AAV2-neurturin) Trial in Parkinson's Disease
SAN DIEGO, Feb. 3, 2011 /PRNewswire " To date, approximately 20 percent of the 52 subjects have undergone either CERE-120 administration or sham surgery, with many others enrolled and awaiting surgery. It is anticipated that enrollment will be completed near the end of June 2011." " 'It is encouraging that CERE-120 continues to appear safe and that the new dosing paradigm we implemented seems well-tolerated,' stated Joao Siffert, M.D., Ceregene's vice president, chief medical officer." |
All times are GMT -5. The time now is 02:55 PM. |
Powered by vBulletin Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.
vBulletin Optimisation provided by
vB Optimise v2.7.1 (Lite) -
vBulletin Mods & Addons Copyright © 2024 DragonByte Technologies Ltd.